MSB 1.81% $1.13 mesoblast limited

Ann: MSB Reports Q3 Financial Results and Operational Highlights, page-318

  1. 16,637 Posts.
    lightbulb Created with Sketch. 2374
    Why would the ODAC meeting have been needed at all if the clinical trial evidence had actually "proven" efficacy. ODAC provided an opinion that it might have efficacy.

    So I'm not sure where you get the idea that "potency" was the only issue. The CRL identified a range of issues.
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
$1.13
Change
0.020(1.81%)
Mkt cap ! $1.261B
Open High Low Value Volume
$1.13 $1.14 $1.12 $1.252M 1.107M

Buyers (Bids)

No. Vol. Price($)
3 8196 $1.13
 

Sellers (Offers)

Price($) Vol. No.
$1.13 45641 9
View Market Depth
Last trade - 10.14am 08/07/2024 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.